This discovery suggests that targeting FGFR pathways may offer an exciting new therapeutic approach to addressing persistent neuroinflammation in patients with post-treatment Lyme disease syndrome.

Fanregratinib is stated to be a selective and potent inhibitor that targets FGFR 1, 2, and 3. Its complete rights are being ...

Erdafitinib, also known as Balversa and made by Johnson & Johnson, is recommended in final draft guidance for adults with metastatic or unresectable FGFR-altered urothelial cancer who have previously ...

In mammals, the fibroblast growth factor (FGF)-FGF receptor (FGFR) interactions control many physiological processes during ...

The oral drug – Johnson & Johnson's Balversa (erdafitinib) – will become an option for adults with metastatic or unresectable ...

The green light from the European Commission comes a few months after pan-FGFR inhibitor Balversa (erdafitinib) was cleared for the same indication in the US, with a different label than the drug ...

The recommendation was based on results from the Phase III THOR trial, which compared Balversa to chemotherapy.

While FGFR inhibitors are clinically available, Tonelli cautioned that their effectiveness in intercepting PDAC would first need to be tested in clinical trials before they could be used for this ...

In addition, they showed that treatment with R3Mab reduced the phosphorylation of FGFR substrate 2α and mitogen-activated protein kinase, indicating that FGFR3-mediated signalling was suppressed.

Simcere Zaiming Pharmaceutical Co. Ltd. has received clinical trial approval from China’s National Medical Products Administration (NMPA) for the company’s antibody-drug conjugate (ADC), SIM-0686, for ...